文献速递气道管理术前评估与围术期医学

高流量鼻导管氧疗延长病态肥胖患者全麻诱导的安全无呼吸时间:一项随机对照试验

High-Flow Nasal Oxygen Improves Safe Apnea Time in Morbidly Obese Patients Undergoing General Anesthesia: A Randomized Controlled Trial.
PubMed 文献 · Anesth Analg · 2019-01-01

这项随机对照试验纳入40例BMI≥40 kg/m²的择期手术患者,比较全麻诱导期间高流量鼻导管氧疗(HFNO)与常规面罩给氧的安全无呼吸时间。

要点

  • HFNO组安全无呼吸时间较面罩组延长约76秒(40%)。
  • HFNO组围插管期最低SpO2更高(91.0% vs 88.0%)。
  • 病态肥胖患者全麻诱导应考虑使用高流量鼻导管氧疗。

核心结论

  • 与常规面罩给氧相比,高流量鼻导管氧疗使病态肥胖患者全麻诱导的安全无呼吸时间延长76秒(40%),并提高围插管期最低SpO2。

研究设计与样本

  • 随机对照试验,纳入40例BMI≥40 kg·m⁻²、年龄≥18岁的择期手术患者,比较HFNO与面罩预给氧及无呼吸期间给氧策略。

关键数值与推荐

  • 安全无呼吸时间定义为SpO2降至95%或无呼吸达6分钟(以先达到者为准)。
  • HFNO组预给氧为100%鼻氧3分钟、40 L·min⁻¹,无呼吸期间给氧60 L·min⁻¹;面罩组预给氧为100%氧、目标呼末O2>85%,无呼吸期间不补充氧气。
  • 麻醉诱导使用丙泊酚、瑞芬太尼和罗库溴铵,不进行面罩通气;罗库溴铵后2分钟行视频喉镜检查,喉镜分级III或IV级者排除。

临床怎么用

  • 对病态肥胖患者全麻诱导,可考虑使用高流量鼻导管氧疗以延长安全无呼吸时间并减少低氧血症风险。

局限性

  • 样本量仅40例,且排除了严重合并症、胃反流病、已知困难气道或鼻阻塞患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Morbidly obese patients undergoing general anesthesia are at risk of hypoxemia during anesthesia induction. High-flow nasal oxygenation use during anesthesia induction prolongs safe apnea time in nonobese surgical patients. The primary objective of our study was to compare safe apnea time, between patients given high-flow nasal oxygenation or conventional facemask oxygenation during anesthesia induction, in morbidly obese surgical patients. METHODS: Research ethics board approval was obtained. Elective surgical patients ≥18 years with body mass index ≥40 kg·m were included. Patients with severe comorbidity, gastric reflux disease, known difficult airway, or nasal obstruction were excluded. After obtaining informed consent patients were randomized. In the intervention (high-flow nasal oxygenation) group, preoxygenation was provided by 100% nasal oxygen for 3 minutes at 40 L·minute; in the control group, preoxygenation was delivered using a facemask with 100% oxygen, targeting end-tidal O2 >85%. Anesthesia was induced with propofol, remifentanil, and rocuronium. Bag-mask ventilation was not performed. At 2 minutes after rocuronium, videolaryngoscopy was performed. If the laryngoscopy grade was I or II, laryngoscope was left in place and the study was continued; if grade III or IV was observed, the patient was excluded from the study. During the apnea period, high-flow nasal oxygenation patients received nasal oxygen at 60 L·minute; control group patients received no supplemental oxygen. The primary outcome, safe apnea time, was reached when oxygen saturation measured by pulse oximetry (SpO2) fell to 95% or maximum 6 minutes of apnea. The patient was then intubated. T tests and χ analyses were used to compare groups. P < .05 was considered significant. RESULTS: Forty patients completed the study. Baseline parameters were comparable between groups. Safe apnea time was significantly longer (261.4 ± 77.7 vs 185.5 ± 52.9 seconds; mean difference [95% CI], 75.9 [33.3-118.5]; P = .001) and the minimum peri-intubation SpO2 was higher (91.0 ± 3.5 vs 88.0 ± 4.8; mean difference [95% CI], 3.1 [0.4-5.7]; P = .026) in the high-flow nasal oxygenation group compared to the control group. CONCLUSIONS: High-flow nasal oxygenation, compared to conventional oxygenation, provided a longer safe apnea time by 76 seconds (40%) and higher minimum SpO2 in morbidly obese patients during anesthesia induction. High-flow oxygenation use should be considered in morbidly obese surgical patients.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Wong DT, Dallaire A, Singh KP, et al. High-Flow Nasal Oxygen Improves Safe Apnea Time in Morbidly Obese Patients Undergoing General Anesthesia: A Randomized Controlled Trial. Anesth Analg. 2019. PMID: 31584919. doi:10.1213/ANE.0000000000003966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。